JosephineHHaduongMD

Pediatric Hematology & Oncology • Orange, CA

Pediatric Solid Tumor Oncology

Attending Oncologist

Join to view full profile

Dr. Haduong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Haduong's full profile

Already have an account?

Office
1201 W La Veta Ave
Orange, CA 92868
Phone+1 714-509-8636

Fax+1 714-509-4748

Education & Training

Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 2009 - 2012
Children's Hospital Los AngelesResidency, Pediatrics, 2005 - 2008
University of Pittsburgh School of MedicineClass of 2005

Certifications & Licensure

CA State Medical License 2007 - 2027
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2019 May 17
Completed
Phase 1
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2021 Nov 30
Completed
Phase 1, Phase 2
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

Implications of Implementing Children's Oncology Group Risk Stratification to Patients With Rhabdomyosarcoma Treated on European Paediatric Soft Tissue Sarcoma Study G...
Gianni Bisogno, Veronique Minard-Colin, Josephine Haduong, Ilaria Zanetti, Andrea Ferrari
Pediatric Blood & Cancer. 2024-11-20
6 citations
Children's Oncology Group's 2023 blueprint for research: Soft tissue sarcomas.
Sapna Oberoi, Jacquelyn N Crane, Josephine H Haduong, Erin R Rudzinski, Suzanne L Wolden
Pediatric Blood & Cancer. 2023-09-01
4 citations
Patients with completely resected nongenitourinary low-risk embryonal rhabdomyosarcoma are candidates for reduced duration low-intensity chemotherapy.
Gianni Bisogno, Joerg Fuchs, Roshni Dasgupta, Andrea Ferrari, Josephine H Haduong
Cancer. 2022-12-01

Other Languages

Spanish, Vietnamese